Philippe JEAN-PIERRE

---

• Type de publi. : Article dans une revue
• Date de publi. : 31/01/2024
• Auteurs : Jeremy FraeringVirginie SalnotEmilie-Fleur GautierSem EzinmegnonNicolas ArgyKatell Peoc’hHana ManceauJules AlaoFrançois GuillonneauFlorence Migot-NabiasGwladys I. BertinClaire KamaliddinAgnes AubouyDissou AffolabiBibiane BiokouMichel CotJean-Eudes DegbeloPhilippe DeloronLatifou DramaneJean-François FaucherEmilie GuillochonLudivine HouzeSayeh Jafari-GuemouriSandrine HouzéValentin JosteAnaïs LabrunieYélé LadipoThomas LathiereAchille MassougbodjiAudrey MowendabekaJade PapinBernard PipyPierre-Marie PreuxMarie RaymondeauJade RoyoDarius SossouBrigitte TecherBertin Vianou
• Organismes : Mère et enfant en milieu tropical : pathogènes, système de santé et transition épidémiologique Institut Cochin Plateforme protéomique 3P5 [Institut Cochin] Laboratoire d'Excellence : Biogenèse et pathologies du globule rouge Plateforme protéomique 3P5 [Institut Cochin] Institut Cochin Institut de Biologie Intégrative de la Cellule Groupe de recherche action en santé AP-HP - Hôpital Bichat - Claude Bernard [Paris] Centre de recherche sur l'Inflammation Université Paris Cité Centre de recherche sur l'Inflammation AP-HP - Hôpital Bichat - Claude Bernard [Paris] Centre Hospitalier Universitaire de la Mère et de l'Enfant Lagune Plateforme protéomique 3P5 [Institut Cochin] Mère et enfant en milieu tropical : pathogènes, système de santé et transition épidémiologique Mère et enfant en milieu tropical : pathogènes, système de santé et transition épidémiologique Mère et enfant en milieu tropical : pathogènes, système de santé et transition épidémiologique Cumming School of Medicine [Calgary] Pharmacochimie et Biologie pour le Développement Institut de Recherche Clinique du Bénin [Abomey-Calavi, Bénin] Laboratoire de Référence des Mycobactéries [Cotonou, Benin] Centre Hospitalier Universitaire de la Mère et de l'Enfant Lagune Mère et enfant en milieu tropical : pathogènes, système de santé et transition épidémiologique Institut de Recherche Clinique du Bénin [Abomey-Calavi, Bénin] Mère et enfant en milieu tropical : pathogènes, système de santé et transition épidémiologique Institut de Recherche Clinique du Bénin [Abomey-Calavi, Bénin] Epidémiologie des Maladies Chroniques en zone tropicale Mère et enfant en milieu tropical : pathogènes, système de santé et transition épidémiologique Mère et enfant en milieu tropical : pathogènes, système de santé et transition épidémiologique Mère et enfant en milieu tropical : pathogènes, système de santé et transition épidémiologique Nuclear Medicine Department [Hôpital Bichat - Claude Bernard] Mère et enfant en milieu tropical : pathogènes, système de santé et transition épidémiologique Epidémiologie des Maladies Chroniques en zone tropicale Centre Hospitalier Universitaire de la Mère et de l'Enfant Lagune Service d'Ophtalmologie [CHU Limoges] Institut de Recherche Clinique du Bénin [Abomey-Calavi, Bénin] Hopital de la Mère et de l’Enfant - Limoges Mère et enfant en milieu tropical : pathogènes, système de santé et transition épidémiologique Centre Hospitalier Universitaire de Zone d'Abomey Calavi / Sô-Ava Epidémiologie des Maladies Chroniques en zone tropicale Epidémiologie des Maladies Chroniques en zone tropicale Centre Hospitalier Universitaire de Zone d'Abomey Calavi / Sô-Ava Institut de Recherche Clinique du Bénin [Abomey-Calavi, Bénin] Mère et enfant en milieu tropical : pathogènes, système de santé et transition épidémiologique Institut de Recherche Clinique du Bénin [Abomey-Calavi, Bénin]
• Publié dans EMBO Molecular Medicine le 23/10/2020

---

Résumé : Abstract Cerebral malaria (CM), the most lethal complication of Plasmodium falciparum severe malaria (SM), remains fatal for 15–25% of affected children despite the availability of treatment. P. falciparum infects and multiplies in erythrocytes, contributing to anemia, parasite sequestration, and inflammation. An unbiased proteomic assessment of infected erythrocytes and plasma samples from 24 Beninese children was performed to study the complex mechanisms underlying CM. A significant down-regulation of proteins from the ubiquitin–proteasome pathway and an up-regulation of the erythroid precursor marker transferrin receptor protein 1 ( TFRC ) were associated with infected erythrocytes from CM patients. At the plasma level, the samples clustered according to clinical presentation. Significantly, increased levels of the 20S proteasome components were associated with SM. Targeted quantification assays confirmed these findings on a larger cohort ( n = 340). These findings suggest that parasites causing CM preferentially infect reticulocytes or erythroblasts and alter their maturation. Importantly, the host plasma proteome serves as a specific signature of SM and presents a remarkable opportunity for developing innovative diagnostic and prognostic biomarkers.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 31/01/2024
• Auteurs : Pierre-Marie WardynJean-Louis EdmeVirginie de BrouckerNathalie Chérot-KornobisDavid RingevalPhilippe AmouyelAnnie SobaszekLuc DauchetSébastien Hulo
• Organismes : Impact de l'environnement chimique sur la santé humaine - ULR 4483 Centre Hospitalier Régional Universitaire [CHU Lille] Impact de l'environnement chimique sur la santé humaine - ULR 4483 Impact de l'environnement chimique sur la santé humaine - ULR 4483 Centre Hospitalier Régional Universitaire [CHU Lille] Impact de l'environnement chimique sur la santé humaine - ULR 4483 Centre Hospitalier Régional Universitaire [CHU Lille] Impact de l'environnement chimique sur la santé humaine - ULR 4483 Centre Hospitalier Régional Universitaire [CHU Lille] Facteurs de Risque et Déterminants Moléculaires des Maladies liées au Vieillissement - U 1167 Centre Hospitalier Régional Universitaire [CHU Lille] Impact de l'environnement chimique sur la santé humaine - ULR 4483 Centre Hospitalier Régional Universitaire [CHU Lille] Facteurs de Risque et Déterminants Moléculaires des Maladies liées au Vieillissement - U 1167 Centre Hospitalier Régional Universitaire [CHU Lille] Impact de l'environnement chimique sur la santé humaine - ULR 4483 Centre Hospitalier Régional Universitaire [CHU Lille]
• Publié dans Journal of Occupational Medicine and Toxicology le 24/10/2020

---

Résumé : Abstract Objective To describe the proportions of subjects exposed to crystalline silica and the sectors of activity concerned between 1965 and 2010 in a sample of the general French population. Methods We included 2942 participants aged 40 to 65 years, recruited at random from electoral rolls, from the French general population in the cross-sectional ELISABET study between 2011 and 2013. The proportions of subjects exposed to crystalline silica and their sectors of activity were determined on the basis of their career history and the use of the Matgéné job-exposure matrix. Results In the total sample, occupational exposure to crystalline silica was found for 291 subjects (9.9%) between 1965 and 2010, with a predominance of men (20.2% of exposed subjects among men (282 out of 1394) versus 0.6% among women (9 out of 1548)). The highest proportion of participants exposed to crystalline silica was reached in 1980 with 6.1% and then decreases to 4.4% in 2010. Among men, the most frequently exposed sectors of activity were manufacture of basic metals (41.5% of exposed men (117 out of 282)), specialised construction activities (23.1% of exposed men (65 out of 282)) and construction of buildings (14.2% of exposed men (40 out of 282)). Conclusions Although the proportion of workers exposed to crystalline silica has been decreasing since the 1980s, it is still significant at least until 2010, particularly in the construction sector, and further research is needed to improve the monitoring of workers who are or have been exposed to crystalline silica.

---

Fichiers liés : main.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 30/01/2024
• Auteurs : Philippe DamierBertrand DegosGiovanni CastelonovoMathieu AnheimIsabelle BenatruNicolas CarrièreOlivier ColinLuc DefebvreMarie DeverdalAlexandre EusebioVanessa FerrierCaroline GiordanaJean-Luc HouetoSeverine Le DilyMarie MonginClaire ThiriezChristine TranchantDenis RavelJean-Christophe CorvolOlivier RascolYehezkel Ben Ari
• Organismes : Centre d'investigation clinique (CIC) de Nantes -CIC Plurithématique Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Nantes Université Hôpital Avicenne [AP-HP] Centre Hospitalier Universitaire de Nîmes Service de Neurologie [Strasbourg] Fédération de Médecine Translationnelle de Strasbourg Institut de Génétique et de Biologie Moléculaire et Cellulaire CIC Poitiers – Centre d'investigation clinique de Poitiers (CIC 1402) Lille Neurosciences & Cognition - U 1172 Centre Hospitalier de Brive-la-Gaillarde Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U837 Centre Hospitalier Universitaire de Nîmes Aix Marseille Université Service de Neurologie [CHU Nice] Service de Neurologie [CHU Nice] Epidémiologie des Maladies Chroniques en zone tropicale Centre d'investigation clinique (CIC) de Nantes -CIC Plurithématique Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Nantes Université Sorbonne Université Service de Neurologie [CHU Caen] Service de Neurologie [Strasbourg] Fédération de Médecine Translationnelle de Strasbourg Institut de Génétique et de Biologie Moléculaire et Cellulaire CHU Pitié-Salpêtrière [AP-HP] Sorbonne Université Institut du Cerveau = Paris Brain Institute Centre Hospitalier Universitaire de Toulouse
• Publié dans Movement Disorders le 31/10/2020

---

Résumé : Background :Acting on the main target of dopaminergic cells, the striatal γ-aminobutyric acid (GABA)-ergic cells, might be a new way to treat persons with Parkinson's disease (PD).Objective :The objective of this study was to assess the efficacy of bumetanide, an Na–K–Cl cotransporter (NKCC1) inhibitor, to improve motor symptoms in PD.Methods :This was a 4-month double-blind, randomized, parallel-group, placebo-controlled trial of 1.75 to 3 mg/day bumetanide as an adjunct to levodopa in 44 participants with PD and motor fluctuations.Results :Compared to the baseline, the mean change in OFF Movement Disorder Society Unified Parkinson's Disease Rating Scale Part III score after 4 months of treatment (primary endpoint) did not improve significantly compared with placebo. No changes between participants treated with bumetanide and those treated with placebo were observed for most other outcome measures. Despite no relevant safety signals, bumetanide was poorly tolerated.Conclusions :There was no evidence in this study that bumetanide has efficacy in improving motor symptoms of PD. © 2024 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

---

Fichiers liés : A Double‐Blind Randomized Placebo‐Controlled Trial of Bumetanide in Parkinson s.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 29/01/2024
• Auteurs : Armelle GUENEGOU ARNOUXJuliette MurrisStephane BéchetCamille JungJohann AuchabieJulien DupeyratNadia AnguelPierre AsfarJulio BadieDorothée CarpentierBenjamin ChoustermanJeremy BourenneAgathe DelboveJérôme DevaquetNicolas DeyeGuillaume DumasAnne-Florence DureauJean-Baptiste LascarrouStéphane LegrielChristophe GuittonCaroline Jannière-NarteyJean-Pierre QuenotJean-Claude LacheradeJulien MaizelArmand Mekontso-DessapBruno MourvillierPhilippe PetuaGaetan PlantefeveJean-Christophe RichardAlexandre RobertClément SaccheriLy van Phach VongSandrine KatsahianFrédérique Schortgen
• Organismes : CIC - HEGP Unité de Recherche Clinique et Centre Investigation Clinique-Epidémiologie Health data- and model- driven Knowledge Acquisition PIERRE FABRE Université Paris Cité Association Clinique et Thérapeutique Infantile du Val de Marne Centre Hospitalier Intercommunal de Créteil Centre Hospitalier de Cholet Centre Hospitalier de Cholet Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre] Centre Hospitalier Universitaire d'Angers Hôpital Nord Franche-Comté [Hôpital de Trévenans] CHU Rouen Hôpital Lariboisière-Fernand-Widal [APHP] Hôpital de la Timone [CHU - APHM] Centre hospitalier Bretagne Atlantique (Morbihan) Hôpital Foch [Suresnes] Service de Réanimation Médicale et Toxicologique [Hôpital Lariboisière] Hôpital Michallon Groupe hospitalier de la région de Mulhouse et Sud-Alsace Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Service de réanimation [CH Versailles] Service Réanimation médico-chirurgicale [CH Le Mans] Centre Hospitalier Libourne Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand Centre Hospitalier Départemental - Hôpital de La Roche-sur-Yon Médecine Intensive-Réanimation [CHU Amiens] CHU Henri Mondor [Créteil] Hôpital universitaire Robert Debré [Reims] Centre Hospitalier de Bigorre [Tarbes] Centre hospitalier Victor Dupouy [Centre hospitalier d'Argenteuil] Université de Lyon Hôpital Pasteur [Nice] Centre Hospitalier Universitaire de Nice Grand Hôpital de l'Est Francilien Health data- and model- driven Knowledge Acquisition CIC - HEGP Hôpital Européen Georges Pompidou [APHP] Centre de Recherche des Cordeliers Centre Hospitalier Intercommunal de Créteil
• Publié dans BMJ Open le 26/10/2020

---

Résumé : Introduction Fever treatment is commonly applied in patients with sepsis but its impact on survival remains undetermined. Patients with respiratory and haemodynamic failure are at the highest risk for not tolerating the metabolic cost of fever. However, fever can help to control infection. Treating fever with paracetamol has been shown to be less effective than cooling. In the SEPSISCOOL pilot study, active fever control by external cooling improved organ failure recovery and early survival. The main objective of this confirmatory trial is to assess whether fever control at normothermia can improve the evolution of organ failure and mortality at day 60 of febrile patients with septic shock. This study will compare two strategies within the first 48 hours of septic shock: treatment of fever with cooling or no treatment of fever. Methods and analysis SEPSISCOOL II is a pragmatic, investigator-initiated, adaptive, multicentre, open-label, randomised controlled, superiority trial in patients admitted to the intensive care unit with febrile septic shock. After stratification based on the acute respiratory distress syndrome status, patients will be randomised between two arms: (1) cooling and (2) no cooling. The primary endpoint is mortality at day 60 after randomisation. The secondary endpoints include the evolution of organ failure, early mortality and tolerance. The target sample size is 820 patients. Ethics and dissemination The study is funded by the French health ministry and was approved by the ethics committee CPP Nord Ouest II (Amiens, France). The results will be submitted for publication in peer-reviewed journals. Trial registration number NCT04494074 .

---

Fichiers liés : e069430.full.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 29/01/2024
• Auteurs : Luc DesmedtMatthieu RaymondAurélie Le ThuautPierre AsfarCédric DarreauFlorian ReizineGwenhaël ColinJohann AuchabieJulien LorberBéatrice La CombePierre KergoatBaptiste HourmantAgathe DelboveAurélien FrérouJean MorinPierre Yves ErgreteauPhilippe SeguinMaëlle MartinJean ReignierJean-Baptiste LascarrouEmmanuel Canet
• Organismes : Hôtel-Dieu de Nantes CEA Le Ripault Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Centre Hospitalier Universitaire d'Angers Centre Hospitalier Le Mans (CH Le Mans) Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Centre Hospitalier Départemental - Hôpital de La Roche-sur-Yon After ROSC research network [Paris, France] Centre Hospitalier de Cholet Centre Hospitalier de Lorient Centre hospitalier Bretagne Atlantique (Morbihan) Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Centre d'Investigation Clinique [Rennes] Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Université de Rennes - Faculté des sciences pharmaceutiques et biologiques Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Motricité, interactions, performance UR 4334 / Movement - Interactions - Performance Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Motricité, interactions, performance UR 4334 / Movement - Interactions - Performance Centre Hospitalier Universitaire de Nantes = Nantes University Hospital
• Publié dans Annals of Intensive Care le 23/10/2020

---

Résumé : Background - Recent studies identified coronavirus disease 2019 (COVID-19) as a risk factor for invasive pulmonary aspergillosis (IPA) but produced conflicting data on IPA incidence and impact on patient outcomes. We aimed to determine the incidence and outcomes of COVID-19-associated pulmonary aspergillosis (CAPA) in mechanically ventilated patients. Methods - We performed a multicenter retrospective observational cohort study in consecutive adults admitted to 15 French intensive care units (ICUs) in 2020 for COVID-19 requiring mechanical ventilation. CAPA was diagnosed and graded according to 2020 ECMM/ISHAM consensus criteria. The primary objective was to determine the incidence of proven/probable CAPA, and the secondary objectives were to identify risk factors for proven/probable CAPA and to assess associations between proven/probable CAPA and patient outcomes. Results - The 708 included patients (522 [73.7%] men) had a mean age of 65.2 ± 10.8 years, a median mechanical ventilation duration of 15.0 [8.0-27.0] days, and a day-90 mortality rate of 28.5%. Underlying immunosuppression was present in 113 (16.0%) patients. Corticosteroids were used in 348 (63.1%) patients. Criteria for probable CAPA were met by 18 (2.5%) patients; no patient had histologically proven CAPA. Older age was the only factor significantly associated with probable CAPA (hazard ratio [HR], 1.04; 95% CI 1.00-1.09; P = 0.04). Probable CAPA was associated with significantly higher day-90 mortality (HR, 2.07; 95% CI 1.32-3.25; P = 0.001) but not with longer mechanical ventilation or ICU length of stay. Conclusion - Probable CAPA is a rare but serious complication of severe COVID-19 requiring mechanical ventilation and is associated with higher day-90 mortality.

---

Fichiers liés : s13613-023-01229-3.pdf

---

Source

---

• Type de publi. : Communication dans un congrès
• Date de publi. : 27/01/2024
• Auteurs : Gabriel MenneratLaurent BizetBenoît MahieuAlexandre DobrocDominique LupinskiDenis BalitskyPhilippe VillevalMagali LozanoFatima AlahyaneAurélien HouardJean-Pierre Wolf
• Organismes : Centre d'études scientifiques et techniques d'Aquitaine (CESTA-CEA) Laboratoire Interactions, Dynamiques et Lasers (ex SPAM) Serveurs Laser Laboratoire d'Optique Appliquée Interaction Laser-Matière Laboratoire d'Optique Appliquée Interaction Laser-Matière Cristal Laser Cristal Laser Cristal Laser Cristal Laser Laboratoire d'Optique Appliquée Interaction Laser-Matière Laboratoire d'Optique Appliquée Interaction Laser-Matière Laboratoire d'Optique Appliquée Interaction Laser-Matière Group of Applied Physics [Geneva]

---

Résumé : We report on high average-power, high-energy picosecond fourth-harmonic generation in LBO. The first stages of a Yb:YAG laser chain operating at 1 kHz repetition rate generate few-picosecond 220 mJ chirped pulses at 1030 nm fundamental wavelength. They are frequency-converted in a cascade of three LBO crystals to generate the second-, third-, and fourth harmonics at 515 nm, 343 nm and 257 nm respectively. Crystals thicknesses and angular phase matching detuning were calculated as a function of pulse duration through broadband nonlinear optical numerical simulations. Last crystal is both conduction-cooled on edge and surface-cooled at center through forced-air flow to mitigate heating due to nonlinear absorption in the deep-UV and reduce temperature gradients. Chirped-pulse duration was experimentally adjusted to achieve stable 20% overall conversion efficiency. Near-field beam profiles were continuously recorded at 10 Hz, for all four wavelengths involved, together with corresponding energies, showing no significant beam degradation over 50 hours. Temperatures of the two last crystals were monitored and will help optimize surface cooling for future power ramping-up.

---

Fichiers liés : Proceedings12869-40 - 45 W average-power, high-energy deep-UV generation at 257 nm in LBO.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 25/01/2024
• Auteurs : Yara SaadeOmar DerazEirini ChatzopoulouHélène RangéPierre BoutouyrieMarie -Cecile PerierCatherine GuiboutFrédérique ThomasNicolas DanchinXavier JouvenPhilippe BouchardJean‐philippe Empana
• Organismes : Hôpital Fondation Adolphe de Rothschild = Adolphe de Rothschild Foundation Hospital Paris-Centre de Recherche Cardiovasculaire Pathologies, imagerie et biothérapies oro-faciales = Orofacial pathologies, imaging and biotherapies Pathologies, imagerie et biothérapies oro-faciales = Orofacial pathologies, imaging and biotherapies Fonctions oncogéniques de la signalisation beta-caténine dans le foie = Oncogenic funtions of beta-catenin signaling in the liver [CRC] Nutrition, Métabolismes et Cancer Paris-Centre de Recherche Cardiovasculaire Paris-Centre de Recherche Cardiovasculaire Paris-Centre de Recherche Cardiovasculaire Département d’Oncologie Médicale [IPC, Marseille] Paris-Centre de Recherche Cardiovasculaire Pathologies, imagerie et biothérapies oro-faciales = Orofacial pathologies, imaging and biotherapies Paris-Centre de Recherche Cardiovasculaire
• Publié dans Community Dentistry and Oral Epidemiology le 30/10/2020

---

Résumé : Objectives: To examine the association between life-course body silhouette changes and oral conditions in adulthood.Methods: At study recruitment (2008-2012), 5430 adults underwent a full-mouth clinical examination and recalled their body silhouettes at ages 8, 15, 25, 35 and 45. Life-course trajectories of body silhouettes were computed using group-based trajectory modelling. Gingival inflammation, dental plaque, masticatory units, numbers of healthy, missing, decayed and filled teeth at study recruitment were clustered. The associations between body silhouette trajectories and clusters of oral conditions were assessed by multinomial logistic regression.Results: The final analysis included 4472 participants. Five body silhouette trajectories were established: lean-stable (30.0%), lean-increased (19.3%), moderate stable (18.1%), lean-marked increased (25.8%) and heavy stable (6.7%). Three clusters of oral conditions were identified: optimal oral health and preserved masticatory capacity (70.0%, cluster 1), moderate oral health and moderately impaired masticatory capacity (25.4%, cluster 2) and poor oral health and severely impaired masticatory capacity (4.7%, cluster 3). Participants with a lean-increased trajectory were 58% more likely than those with a lean-stable trajectory to be in cluster 3 (aOR 1.58 [95% CI 1.07; 2.35]) relative to cluster 1, independently of covariates measured at study recruitment and including age, sex, smoking, socioeconomic status, BMI, hypertension, type 2 diabetes, cholesterol and triglycerides.Conclusions: A life-course lean-increased body silhouette trajectory is associated with higher likelihood of poor oral health and severely impaired masticatory capacity in adulthood.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 25/01/2024
• Auteurs : Samy BencherquiSelene BaroneLucia CevidanesJean-Philippe PerrinPierre CorreHélios Bertin
• Organismes : Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Università degli Studi "Magna Graecia" di Catanzaro = University of Catanzaro Université du Michigan = University of Michigan [Ann Arbor] Centre Hospitalier Universitaire de Nantes = Nantes University Hospital RMeS - Regenerative Medicine of Bone Tissues Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes-Angers
• Publié dans Clinical Oral Investigations le 30/10/2020

---

Résumé : Objectives: Among the existing techniques for the correction of mandibular posterior vertical insufficiency (PVI), the intra-oral ramus vertical lengthening osteotomy (IORVLO) can be proposed as it allows simultaneous correction of mandibular height and retrusion. This study assessed the 3D morpho-anatomical changes of the ramus-condyle unit and occlusal stability after IORVLO. Materials and methods: This retrospective analysis compared immediate and 1-year post-operative 3D CBCT reconstructions. The analysis focused on the condylar height (primary endpoint) and on the changes in condylar (condylar diameter, condylar axis angle) and mandibular (ramus height, Frankfort-mandibular plane angle, gonion position, intergonial distance, angular remodeling) parameters. Additionally, this analysis investigated the maxillary markers and occlusal stability. Results: On the 38 condyles studied in 21 included patients (mean age 23.7 ± 3.9 years), a condylar height (CH) loss of 0.66 mm (p < 0,03) was observed, with no correlation with the degree of ramus lengthening (mean 13.3 ± 0.76 mm). Only one patient presented an occlusal relapse of Class II, but a 3.4 mm (28%) condylar diameter loss and a 33% condylar volume reduction with loss of 1 mm and 3.4 mm in CH and condyle diameter, respectively. A mean 3.56 mm (p < 0.001) decrease in ramus height was noted, mainly due to bone resorption in the mandibular angles. Conclusion: This study confirms the overall stability obtained with IORVLO for the correction of PVI. Clinical relevance: This study aims to precise indication of IORVLO, and to validate the clinical and anatomical stability of results.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 24/01/2024
• Auteurs : G. JonesColin SnodgrassC TubianaMichael KüppersHideyo KawakitaLuisa LaraJessica AgarwalNicolas AndréNicholas AttreeUli AusterStefano BagnuloMichele T BannisterArnaud BethNeil BowlesAndrew CoatesLuigi ColangeliCarlos Corral van DammeVania da DeppoJohan de KeyserVincenzo Della CorteNiklas J. T. EdbergMohamed Ramy El-MaarrySara FaggiM. FulleRyu FunaseMarina GalandCharlotte GoetzOlivier GroussinAurélie Guilbert-LepoutreP. HenriS. KasaharaAkos KereszturiMark KidgerMatthew M KnightRosita KokotanekovaI. KolmasovaKonrad KossackiEkkehard KührtYuna KwonFiorangela La ForgiaAnny Chantal Levasseur-RegourdManuela LippiAndrea LongobardoRaphael MarschallMarek MorawskiOlga MuñozAntti NäsiläH. NilssonC. OpitomMihkel PajusaluAntoine PommerolLubomír PřechNicola RandoFrancesco RattiHanna RothkaehlA. RotundiMartin RubinNaoya SakataniJoan Pau SánchezC. Simon WedlundAnamarija StankovNicolas ThomasImre TothGeronimo L VillanuevaJean-Baptiste VincentM. VolwerkP. WurzArno WieldersKazuo YoshiokaKonrad AleksiejukFernando AlvarezCarine AmorosShahid AslamBarbara AtamaniukJędrzej BaranTomasz BarcińskiThomas BeckThomas BehnkeMartin BerglundIvano BertiniMarcin BiedaPiotr BinczykMartin-Diego BuschAndrei CacoveanMaria Teresa CapriaC M CarrJosé María Castro MarínMatteo CeriottiPaolo ChioettoAgata Chuchra-KonradLorenzo CocolaFabrice ColinChiaki CrewsVictoria CrippsEmanuele CupidoAlberto DassattiBjörn DavidssonThierry de RocheShaosui XuSimone del TognoFrederik DhoogheKerri Donaldson HannaA. I ErikssonAndrey FedorovEstela Fernández-ValenzuelaStefano FerrettiJohan FloriotFabio FrassettoJesper FredrikssonPhilippe GarnierDorota GawełVincent GénotThomas GerberKarl-Heinz GlassmeierMikael GranvikBenjamin GrisonHerbert GunellTedjani HachemiChristian HagenRajkumar HajraYuki HaradaJohann HasibaNico HaslebacherMiguel Luis Herranz de la RevillaDaniel HestrofferTilak HewagamaCarrie HoltStubbe HviidIaroslav IakubivskyiL InnoPatrick G. J. IrwinStavro IvanovskiJiri JanskyIrmgard JernejHarald JeszenszkyJaime JimenézL. JordaMihkel KamaShingo KamedaMichael KelleyKamil KlepackiTomáš KohoutH. KojimaTomasz KowalskiMasaki KuwabaraMichal LadnoGunter LakyHelmut LammerRadek LanBenoit LavraudMonica LazzarinOlivier Le DuffQiu Mei LeeCezary LesniakZoe LewisZhong-Yi LinTim ListerStephen LowryWerner MagnesJohannes MarkkanenIgnacio Martinez NavajasZita MartinsAyako MatsuokaBarbara MatyjasiakC. MazelleE Mazzotta EpifaniMirko MeierHarald MichaelisMarco MicheliAlessandra MiglioriniAude-Lyse MilletFreddy MorenoStefano MottolaBruno MoutounaickK. MuinonenDaniel R MüllerG. MurakamiNaofumi MurataKamil MyszkaShintaro NakajimaZoltán NemethArtiom NikolajevSimone NorderaDan OhlssonAire OleskHarald OttacherNaoya OzakiChristophe OziolManish R PatelAditya Savio PaulA. PenttiläClaudio PernecheleJoakim PetersonEnrico PetraglioAlice Maria PiccirilloFerdinand PlaschkeSzymon PolakF PostbergHerman ProosaSilvia ProtopapaWalter PuccioSylvain RanvierSean N. RaymondIngo RichterMartin RiederRoberto RigamontiIrene Ruiz RodriguezOndřej SantolíkTakahiro SasakiRolf SchrödterKatherine ShirleyAndris SlavinskisBalint SodorJan SoučekPeter StephensonLinus StöckliPaweł SzewczykGabor TroznaiLudek UhlirNaoto UsamiAris ValavanoglouJ. VaverkaWei WangXiao‐dong WangM. WieserGaëtan WattieauxSebastian WolfHajime YanoIchiro YoshikawaVladimir ZakharovTomasz ZawistowskiPaola ZuppellaGiovanna RinaldiHantao Ji
• Organismes : Mullard Space Science Laboratory Centre for Planetary Sciences [UCL/Birkbeck] The University of Edinburgh Istituto di Astrofisica e Planetologia Spaziali - INAF European Space Astronomy Centre University of Tokyo [Tokyo] = Tōkyō teikoku daigaku Instituto de Astrofísica de Andalucía = Institute of Astrophysics of Andalusia Institut für Geophysik und Extraterrestrische Physik [Braunschweig] Institut de recherche en astrophysique et planétologie Instituto de Astrofísica de Andalucía = Institute of Astrophysics of Andalusia Institut für Geophysik und Extraterrestrische Physik [Braunschweig] Armagh Observatory [Armagh] University of Canterbury [Christchurch] Imperial College London Department of Physics [Oxford] Mullard Space Science Laboratory Centre for Planetary Sciences [UCL/Birkbeck] European Space Research and Technology Centre European Space Research and Technology Centre CNR Istituto di Fotonica e Nanotecnologie [Padova] Belgian Institute for Space Aeronomy / Institut d'Aéronomie Spatiale de Belgique Istituto di Astrofisica e Planetologia Spaziali - INAF Swedish Institute of Space Physics [Kiruna] Khalifa University of Science and Technology = Khalifa University [Abou Dabi] NASA Goddard Space Flight Center INAF - Osservatorio Astronomico di Trieste Institute of Space and Astronautical Science Imperial College London European Space Research and Technology Centre Laboratoire d'Astrophysique de Marseille Laboratoire de Géologie de Lyon - Terre, Planètes, Environnement Joseph Louis LAGRANGE University of Tokyo [Tokyo] = Tōkyō teikoku daigaku Konkoly Observatory European Space Astronomy Centre United States Naval Academy Institute of Astronomy of the Bulgarian Academy of Sciences Institute of Atmospheric Physics of the Czech Academy of Sciences Uniwersytet Warszawski [Polska] = University of Warsaw [Poland] = Université de Varsovie [Pologne] DLR Institute of Optical Sensor Systems Infrared Processing and Analysis Center DLR Institute of Optical Sensor Systems PLANETO - LATMOS Institut für Geophysik und Extraterrestrische Physik [Braunschweig] Istituto di Astrofisica e Planetologia Spaziali - INAF Joseph Louis LAGRANGE Space Research Centre of Polish Academy of Sciences Instituto de Astrofísica de Andalucía = Institute of Astrophysics of Andalusia VTT Technical Research Centre of Finland Swedish Institute of Space Physics [Kiruna] The University of Edinburgh Tartu Observatory Physics Institute [Bern] Univerzita Karlova [Praha, Česká republika] = Charles University [Prague, Czech Republic] European Space Research and Technology Centre European Space Research and Technology Centre Space Research Centre of Polish Academy of Sciences Dipartimento di Scienze e Tecnologie [Napoli] Physics Institute [Bern] Institute of Space and Astronautical Science Institut Supérieur de l'Aéronautique et de l'Espace Space Research Institute of Austrian Academy of Sciences European Space Research and Technology Centre Space Research and Planetary Sciences [Bern) Konkoly Observatory Research Centre for Astronomy and Earth Sciences [Budapest] NASA Goddard Space Flight Center DLR Institut für Planetenforschung Space Research Institute of Austrian Academy of Sciences Space Research and Planetary Sciences [Bern) European Space Research and Technology Centre University of Tokyo [Tokyo] = Tōkyō teikoku daigaku Space Research Centre of Polish Academy of Sciences Instituto de Astrofísica de Andalucía = Institute of Astrophysics of Andalusia Institut de recherche en astrophysique et planétologie NASA Goddard Space Flight Center Space Research Centre of Polish Academy of Sciences Space Research Centre of Polish Academy of Sciences Space Research Centre of Polish Academy of Sciences Space Research and Planetary Sciences [Bern) DLR Institut für Planetenforschung Swedish Institute of Space Physics [Uppsala / Kiruna] Dipartimento di Scienze e Tecnologie [Napoli] Creotech Instruments SA Creotech Instruments SA Space Research and Planetary Sciences [Bern) DLR Institut für Planetenforschung Istituto di Astrofisica e Planetologia Spaziali - INAF Department of Physics [Imperial College London] Instituto de Astrofísica de Andalucía = Institute of Astrophysics of Andalusia University of Glasgow CNR Istituto di Fotonica e Nanotecnologie [Padova] Space Research Centre of Polish Academy of Sciences CNR Istituto di Fotonica e Nanotecnologie [Padova] Laboratoire de Physique et Chimie de l'Environnement et de l'Espace The Open University [Milton Keynes, UK] Swedish Institute of Space Physics [Uppsala / Kiruna] Department of Physics [Imperial College London] School of Engineering and Management Vaud Jet Propulsion Laboratory Space Research and Planetary Sciences [Bern) Laboratory for Atmospheric and Space Physics [Boulder] DLR Institut für Planetenforschung Belgian Institute for Space Aeronomy / Institut d'Aéronomie Spatiale de Belgique Department of Physics [Orlando] Swedish Institute of Space Physics [Uppsala / Kiruna] Institut de recherche en astrophysique et planétologie Florida Space Institute [Orlando] Dipartimento di Scienze e Tecnologie [Napoli] Laboratoire d'Astrophysique de Marseille CNR Istituto di Fotonica e Nanotecnologie [Padova] Swedish Institute of Space Physics [Uppsala / Kiruna] Institut de recherche en astrophysique et planétologie Institut Universitaire de Technologie - Paul Sabatier Creotech Instruments SA Institut de recherche en astrophysique et planétologie Space Research and Planetary Sciences [Bern) Institut für Geophysik und Extraterrestrische Physik [Braunschweig] Department of Physics [Helsinki] Asteroid Engineering Laboratory [Kiruna] Institute of Atmospheric Physics of the Czech Academy of Sciences Umeå University = Umeå Universitet Laboratoire de Physique et Chimie de l'Environnement et de l'Espace Space Research Institute of Austrian Academy of Sciences Indian Institute of Technology Indore Kyōto daigaku = Kyoto University Space Research Institute of Austrian Academy of Sciences Space Research and Planetary Sciences [Bern) Instituto de Astrofísica de Andalucía = Institute of Astrophysics of Andalusia Institut de Mécanique Céleste et de Calcul des Ephémérides NASA Goddard Space Flight Center Las Cumbres Observatory DLR Institut für Planetenforschung Tartu Observatory Dipartimento di Scienze e Tecnologie [Napoli] Department of Physics [Oxford] INAF - Osservatorio Astronomico di Trieste Institute of Atmospheric Physics of the Czech Academy of Sciences Space Research Institute of Austrian Academy of Sciences Space Research Institute of Austrian Academy of Sciences Instituto de Astrofísica de Andalucía = Institute of Astrophysics of Andalusia Laboratoire d'Astrophysique de Marseille University College London [UCL] Tartu Observatory Rikkyo University [Tokyo] Department of Astronomy [College Park] Creotech Instruments SA Department of Geosciences and Geography [Helsinki] Institute of Geology of the Czech Academy of Sciences Research Institute for Sustainable Humanosphere Space Research Centre of Polish Academy of Sciences Rikkyo University [Tokyo] Creotech Instruments SA Space Research Institute of Austrian Academy of Sciences Space Research Institute of Austrian Academy of Sciences Institute of Atmospheric Physics of the Czech Academy of Sciences Laboratoire d'Astrophysique de Bordeaux [Pessac] Dipartimento di Fisica e Astronomia "Galileo Galilei" Laboratoire de Physique et Chimie de l'Environnement et de l'Espace Institut de recherche en astrophysique et planétologie Creotech Instruments SA Department of Physics [Imperial College London] Institute of Astronomy [Taiwan] Las Cumbres Observatory University of Kent [Canterbury] Space Research Institute of Austrian Academy of Sciences Institut für Geophysik und Extraterrestrische Physik [Braunschweig] Instituto de Astrofísica de Andalucía = Institute of Astrophysics of Andalusia Centro de Quimica Estrutural Kyōto daigaku = Kyoto University Space Research Centre of Polish Academy of Sciences Institut de recherche en astrophysique et planétologie INAF - Osservatorio Astronomico di Roma Space Research and Planetary Sciences [Bern) DLR Institut für Planetenforschung ESA SSA-NEO Coordination Centre Istituto di Astrofisica e Planetologia Spaziali - INAF Laboratoire de Physique et Chimie de l'Environnement et de l'Espace Instituto de Astrofísica de Andalucía = Institute of Astrophysics of Andalusia DLR Institut für Planetenforschung Institut de recherche en astrophysique et planétologie Department of Physics [Helsinki] Space Research and Planetary Sciences [Bern) Institute of Space and Astronautical Science Institute of Space and Astronautical Science Creotech Instruments SA Institute of Space and Astronautical Science Wigner Fizikai Kutatóközpont = Wigner Research Centre for Physics [Budapest] Tartu Observatory CNR Istituto di Fotonica e Nanotecnologie [Padova] Swedish Institute of Space Physics [Uppsala / Kiruna] Tartu Observatory Space Research Institute of Austrian Academy of Sciences Institute of Space and Astronautical Science Institut de recherche en astrophysique et planétologie The Open University [Milton Keynes, UK] Tartu Observatory Department of Physics [Helsinki] INAF - Osservatorio Astronomico di Padova Swedish Institute of Space Physics [Uppsala / Kiruna] School of Engineering and Management Vaud Dipartimento di Scienze e Tecnologie [Napoli] Institut für Geophysik und Extraterrestrische Physik [Braunschweig] Space Research Centre of Polish Academy of Sciences Freie Universität Berlin = Free University of Berlin Tartu Observatory Southwest Research Institute [Boulder] Swedish Institute of Space Physics [Uppsala / Kiruna] Belgian Institute for Space Aeronomy / Institut d'Aéronomie Spatiale de Belgique Laboratoire d'Astrophysique de Bordeaux [Pessac] Institut für Geophysik und Extraterrestrische Physik [Braunschweig] Space Research and Planetary Sciences [Bern) School of Engineering and Management Vaud Department of Physics [Imperial College London] Institute of Atmospheric Physics of the Czech Academy of Sciences Institute of Space and Astronautical Science DLR Institut für Planetenforschung Department of Physics [Oxford] Tartu Observatory SGF Ltd Institute of Atmospheric Physics of the Czech Academy of Sciences Department of Physics [Imperial College London] Space Research and Planetary Sciences [Bern) Space Research Centre of Polish Academy of Sciences SGF Ltd Institute of Atmospheric Physics of the Czech Academy of Sciences Institute of Space and Astronautical Science Space Research Institute of Austrian Academy of Sciences Univerzita Karlova [Praha, Česká republika] = Charles University [Prague, Czech Republic] Space Research and Planetary Sciences [Bern) Swedish Institute of Space Physics [Uppsala / Kiruna] Swedish Institute of Space Physics [Uppsala / Kiruna] Plasmas Réactifs Hors Equilibre Space Research and Planetary Sciences [Bern) Institute of Space and Astronautical Science University of Tokyo [Tokyo] = Tōkyō teikoku daigaku Laboratoire d'études spatiales et d'instrumentation en astrophysique = Laboratory of Space Studies and Instrumentation in Astrophysics Creotech Instruments SA CNR Istituto di Fotonica e Nanotecnologie [Padova] Istituto di Astrofisica e Planetologia Spaziali - INAF Department of Astrophysical Sciences [Princeton]
• Publié dans Space Science Reviews le 31/10/2020

---

Résumé : Here we describe the novel, multi-point Comet Interceptor mission. It is dedicated to the exploration of a little-processed long-period comet, possibly entering the inner Solar System for the first time, or to encounter an interstellar object originating at another star. The objectives of the mission are to address the following questions: What are the surface composition, shape, morphology, and structure of the target object? What is the composition of the gas and dust in the coma, its connection to the nucleus, and the nature of its interaction with the solar wind? The mission was proposed to the European Space Agency in 2018, and formally adopted by the agency in June 2022, for launch in 2029 together with the Ariel mission. Comet Interceptor will take advantage of the opportunity presented by ESA’s F-Class call for fast, flexible, low-cost missions to which it was proposed. The call required a launch to a halo orbit around the Sun-Earth L2 point. The mission can take advantage of this placement to wait for the discovery of a suitable comet reachable with its minimum $\varDelta $ Δ V capability of $600\text{ ms}^{-1}$ 600 ms − 1 . Comet Interceptor will be unique in encountering and studying, at a nominal closest approach distance of 1000 km, a comet that represents a near-pristine sample of material from the formation of the Solar System. It will also add a capability that no previous cometary mission has had, which is to deploy two sub-probes – B1, provided by the Japanese space agency, JAXA, and B2 – that will follow different trajectories through the coma. While the main probe passes at a nominal 1000 km distance, probes B1 and B2 will follow different chords through the coma at distances of 850 km and 400 km, respectively. The result will be unique, simultaneous, spatially resolved information of the 3-dimensional properties of the target comet and its interaction with the space environment. We present the mission’s science background leading to these objectives, as well as an overview of the scientific instruments, mission design, and schedule.

---

Fichiers liés : s11214-023-01035-0.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 24/01/2024
• Auteurs : Aurelien VoissiereCarlos Alberto Gomez-RocaSylvie ChabaudCéline RodriguezAxelle NkodiaJustine BerthetLaure MontaneAnne-Sophie BidauxIsabelle TreilleuxLauriane EberstCatherine TerretIphigénie KorakisGwenaelle GarinDavid PérolJean-Pierre DelordChristophe CauxBertrand DuboisC. MenetrierNathalie Bendriss-VermarePhilippe Alexandre Cassier
• Organismes : Centre de Recherche en Cancérologie de Lyon Institut Universitaire du Cancer de Toulouse - Oncopole Centre Léon Bérard [Lyon] Centre de Recherche en Cancérologie de Lyon Laboratoire d’immunothérapie du cancer de Lyon (plateforme) Centre de Recherche en Cancérologie de Lyon Laboratoire d’immunothérapie du cancer de Lyon (plateforme) Centre de Recherche en Cancérologie de Lyon Laboratoire d’immunothérapie du cancer de Lyon (plateforme) Centre Léon Bérard [Lyon] Centre Léon Bérard [Lyon] Centre Léon Bérard [Lyon] Centre Léon Bérard [Lyon] Centre Léon Bérard [Lyon] Institut Universitaire du Cancer de Toulouse - Oncopole Centre Léon Bérard [Lyon] Centre Léon Bérard [Lyon] Institut Universitaire du Cancer de Toulouse - Oncopole Centre de Recherche en Cancérologie de Lyon Laboratoire d’immunothérapie du cancer de Lyon (plateforme) Centre de Recherche en Cancérologie de Lyon Laboratoire d’immunothérapie du cancer de Lyon (plateforme) Centre Léon Bérard [Lyon] Centre de Recherche en Cancérologie de Lyon Centre de Recherche en Cancérologie de Lyon Laboratoire d’immunothérapie du cancer de Lyon (plateforme) Centre Léon Bérard [Lyon]
• Publié dans Science Translational Medicine le 23/10/2020

---

Résumé : Tumor-associated macrophages (TAMs) are a critical determinant of resistance to PD-1/PD-L1 blockade. This phase 1 study (MEDIPLEX, NCT02777710) investigated the safety and efficacy of pexidartinib, a CSF-1R–directed tyrosine kinase inhibitor (TKI), and durvalumab (anti–PD-L1) in patients with advanced colorectal and pancreatic carcinoma with the aim to enhance responses to PD-L1 blockade by eliminating CSF-1–dependent suppressive TAM. Forty-seven patients were enrolled. No unexpected toxicities were observed, one (2%) high microsatellite instability CRC patient had a partial response, and seven (15%) patients experienced stable disease as their best response. Increase of CSF-1 concentrations and decrease of CD14 low CD16 high monocytes in peripheral blood mononuclear cells (PBMCs) confirmed CSF-1R engagement. Treatment decreased blood dendritic cell (DC) subsets and impaired IFN-λ/IL-29 production by type 1 conventional DCs in ex vivo TLR3-stimulated PBMCs. Pexidartinib also targets c-KIT and FLT3, both key growth factor receptors of DC development and maturation. In patients, FLT3-L concentrations increased with pexidartinib treatment, and AKT phosphorylation induced by FLT3-L ex vivo stimulation was abrogated by pexidartinib in human blood DC subsets. In addition, pexidartinib impaired the FLT3-L– but not GM-CSF–dependent generation of DC subsets from murine bone marrow (BM) progenitors in vitro and decreased DC frequency in BM and tumor-draining lymph node in vivo. Our results demonstrate that pexidartinib, through the inhibition of FLT3 signaling, has a deleterious effect on DC differentiation, which may explain the limited antitumor clinical activity observed in this study. This work suggests that inhibition of FLT3 should be considered when combining TKIs with immune checkpoint inhibitors.

---

Source